Stock events for Integer Holdings Corp. (ITGR)
In the past six months, Integer Holdings Corp. experienced several stock events, including Q3 2025 earnings beat, a CEO transition, and updated 2025-2027 guidance and outlook. An analyst downgrade occurred following the Q3 results and a weaker-than-expected 2026 outlook. The Board of Directors authorized a share repurchase plan. Integer stock rose after an activist investor reportedly built a stake and urged a sale. There were several insider transactions. The stock's 52-week high was $144.76, and its 52-week low was $62.00, with a closing stock price of $85.23 as of February 5, 2026, and a -39.31% change over the past year.
Demand Seasonality affecting Integer Holdings Corp.’s stock price
The demand for Integer Holdings Corp.'s products and services does not appear to follow traditional seasonal patterns. Instead, demand is influenced by factors such as new product adoption cycles and changes in customer demand. The medical devices industry generally benefits from recurring revenue streams tied to consumables, maintenance services, and technology upgrades.
Overview of Integer Holdings Corp.’s business
Integer Holdings Corporation is a leading medical device contract development and manufacturing organization (CDMO) that designs and manufactures medical devices and components. Its major products span several medical fields, including Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Advanced Surgical, Orthopedics & Portable Medical. The company's brands include Greatbatch Medical® and Lake Region Medical®.
ITGR’s Geographic footprint
Integer Holdings Corp. has a global presence, operating in the United States, Puerto Rico, Costa Rica, and internationally. The company maintains 17 manufacturing sites and 9 research and development centers across four continents.
ITGR Corporate Image Assessment
Integer Holdings Corp. is recognized as one of the largest medical device contract development and manufacturing organizations globally. The company positions itself as a strategic partner committed to enhancing patient lives through innovative, high-quality products and solutions. Integer owns approximately 700 patents, highlighting its focus on innovation. There were no specific events in the past year that significantly impacted its brand reputation, either positively or negatively, beyond its regular business operations and financial performance.
Ownership
Approximately 66.70% of Integer Holdings Corp.'s stock is owned by institutional investors, 0.86% by insiders, and 32.44% by public companies and individual investors. Some of the largest institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Dimensional Fund Advisors Lp, State Street Corp, Alliancebernstein L.P., Invesco Ltd., Earnest Partners LLC, and Viking Global Investors Lp.
Ask Our Expert AI Analyst
Price Chart
$86.68